Sign in to fuzzto save your conversations, follow your research and come back anytime.
Abbott
SectorHealthcare
Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic areas including Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health. The company is structured into four divisions: Primary Care, Specialty Care-Methabolics and Urology, Specialty Care-Neuroscience, and Hospital Care. Abbott India manufactures and markets a wide range of products including Brufen, Prothiaden, Thyronorm, Leptos, Digene, Cremaffin, Influvac, and many others. The company has expanded its product portfolio through launches, acquisitions, and partnerships over the years. Abbott India is engaged in research and development, conducting clinical studies and publishing in medical journals. The company has also been recognized for innovation in the pharmaceutical industry.
In the news
Abbott Settles $670M Infant Formula Lawsuits, Q2 Performance Strong
HDFC Securities Picks ABB India, eClerx Services for Short-Term
Abbott India Q1 profit surges 17% to ₹429 cr, shares down 2.03%
ABB India sees volume-led growth ahead, margin recovery to take time
L&T, SBI Life among top analyst picks for Tuesday trading
ABB India gets hold rating, target price raised to ₹6944
ABB India shares gain 2.39% on strong Q2 performance, record orders
Abbott Labs shares surge 12% on Q2 beat, raised outlook
ABB India falls 2.09% after record India order growth rally
88 stocks turn ex-dividend this week worth ₹1,609.52 payouts
Abbott India Offers 5,250% Dividend with July 24 Record Date
Top 10 Most Bought Stocks: Nvidia, Microsoft Lead May Trading
HDFC Life drops 5th straight session, down 23% YoY
ABB India hits 5-day winning streak, up 22% YoY
Orient Electric Q4 profit surges 29% to ₹40.28 crore
Vedanta Demerger Goes Ex-Date Today: Buy Before April 29
ABB India hits 52-week high on $75M investment plan
5 Stocks Show 36% Upside Potential with Strong Score Improvements
JPMorgan cuts Abbott India target by 19% on growth concerns
ABB India share price target raised 50% by UBS to ₹8,030 amid market volatility
Company insights, generated from the most recent coverage.
FY26 revenue of ₹6,929 Cr (+8.1% YoY) with ₹1,552 Cr net profit shows steady, low-volatility earnings — but it also sets a demanding base that Q2 FY27 has to clear.
₹656/share total dividend (₹525 final plus ₹131 special) reflects a cash-rich, capital-light model where almost all profit is returned to shareholders rather than reinvested.
Appointment of James Wenner and Neeraj Jain with 99.99% shareholder approval at the 82nd AGM removes governance overhang and supports the stable-management narrative.